Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

Lilly is testing bimagrumab alone and in combination with Novo's Wegovy -- a mid-stage trial begun before the acquisition -- ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

The company's famous medicines, diabetes treatment Ozempic and anti-obesity medicine Wegovy, have been on fire. However, some investors are worried that Novo Nordisk will lose significant market ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Long-Term Pick. In this article, we will summarize ...

We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Novo Nordisk (NVO) remains a dominant force in diabetes and obesity treatments, yet the stock is currently trading below its fair value. Despite a recent decline following disappointing trial ...